Phosphatidylinositol 3 kinase delta inhibitors - Pipeline Insight, 2022
![](/report_cover/8047/phosphatidylinositol-3-kinase-delta-inhibitors-pipeline-insight-2022_en.gif)
This report can be delivered to the clients within 3-4 Business Days
DelveInsight’s, “Phosphatidylinositol 3 kinase delta inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in “Phosphatidylinositol 3 kinase delta inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
“Phosphatidylinositol 3 kinase delta inhibitors: Overview
A phosphoinositide 3-kinase inhibitor (PI3K inhibitor) is a class of medical drug that functions by inhibiting one or more of the phosphoinositide 3-kinase enzymes, which are part of the PI3K/AKT/mTOR pathway, an important signalling pathway for many cellular functions such as growth control, metabolism and translation initiation. Within this pathway there are many components, inhibition of which may result in tumor suppression. These anti-cancer drugs are examples of targeted therapy.
Report Highlights
This segment of the “Phosphatidylinositol 3 kinase delta inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
“Phosphatidylinositol 3 kinase delta inhibitors Emerging Drugs
Further product details are provided in the report……..
“Phosphatidylinositol 3 kinase delta inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different “Phosphatidylinositol 3 kinase delta inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
“Phosphatidylinositol 3 kinase delta inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses “Phosphatidylinositol 3 kinase delta inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging “Phosphatidylinositol 3 kinase delta inhibitors drugs.
“Phosphatidylinositol 3 kinase delta inhibitors Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Phosphatidylinositol 3 kinase delta inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in “Phosphatidylinositol 3 kinase delta inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
“Phosphatidylinositol 3 kinase delta inhibitors: Overview
A phosphoinositide 3-kinase inhibitor (PI3K inhibitor) is a class of medical drug that functions by inhibiting one or more of the phosphoinositide 3-kinase enzymes, which are part of the PI3K/AKT/mTOR pathway, an important signalling pathway for many cellular functions such as growth control, metabolism and translation initiation. Within this pathway there are many components, inhibition of which may result in tumor suppression. These anti-cancer drugs are examples of targeted therapy.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence “Phosphatidylinositol 3 kinase delta inhibitors R&D. The therapies under development are focused on novel approaches for “Phosphatidylinositol 3 kinase delta inhibitors.
This segment of the “Phosphatidylinositol 3 kinase delta inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
“Phosphatidylinositol 3 kinase delta inhibitors Emerging Drugs
- Umbralisib: TG Therapeutics
- Parsaclisib: Incyte Corporation
Further product details are provided in the report……..
“Phosphatidylinositol 3 kinase delta inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different “Phosphatidylinositol 3 kinase delta inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on “Phosphatidylinositol 3 kinase delta inhibitors
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
“Phosphatidylinositol 3 kinase delta inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses “Phosphatidylinositol 3 kinase delta inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging “Phosphatidylinositol 3 kinase delta inhibitors drugs.
“Phosphatidylinositol 3 kinase delta inhibitors Report Insights
- “Phosphatidylinositol 3 kinase delta inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing “Phosphatidylinositol 3 kinase delta inhibitors drugs?
- How many “Phosphatidylinositol 3 kinase delta inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of “Phosphatidylinositol 3 kinase delta inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the “Phosphatidylinositol 3 kinase delta inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for “Phosphatidylinositol 3 kinase delta inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
- TG Therapeutics
- Incyte Corporation
- Nanjing Zenshine Pharmaceuticals
- Shanghai Yingli Pharmaceutical
- Bayer HealthCare Pharmaceuticals
- Novartis
- Rhizen Pharmaceuticals
- Secura Bio
- Applied Therapeutics
- Hillstream BioPharma
- Celon pharma
- Yuhan
- Gilead Sciences
- Chia Tai Tianqing Pharmaceutical Group
- Acerta Pharma
- BR 101801
- BeiGene
- Nanjing Sanhome Pharmaceutical
- Hutchison MediPharma
- Calistoga Pharmaceuticals
- Kyowa Kirin
- Umbralisib
- Parsaclisib
- Zandelisib
- ZX 101A
- Linperlisib
- CAL-101
- SHC 014748M
- HMPL-689
- BGB-10188
- BR 101801
- ACP 319
- Copanlisib
- TQ B3525
- Leniolisib
- GS-9820
- Tenalisib
- YH 25248
- Duvelisib
- HSB-501
- AT-104
Introduction
Executive Summary
“Phosphatidylinositol 3 kinase delta inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
“Phosphatidylinositol 3 kinase delta inhibitors – DelveInsight’s Analytical Perspective
Late Stage Products (Preregistration)
Comparative Analysis
Umbralisib: TG Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Tenalisib: Rhizen Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I and I/II)
Comparative Analysis
ZX 101A: Nanjing Zenshine Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
AT-104: Applied Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
“Phosphatidylinositol 3 kinase delta inhibitors Key Companies
“Phosphatidylinositol 3 kinase delta inhibitors Key Products
“Phosphatidylinositol 3 kinase delta inhibitors- Unmet Needs
“Phosphatidylinositol 3 kinase delta inhibitors- Market Drivers and Barriers
“Phosphatidylinositol 3 kinase delta inhibitors- Future Perspectives and Conclusion
“Phosphatidylinositol 3 kinase delta inhibitors Analyst Views
“Phosphatidylinositol 3 kinase delta inhibitors Key Companies
Appendix
Executive Summary
“Phosphatidylinositol 3 kinase delta inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
“Phosphatidylinositol 3 kinase delta inhibitors – DelveInsight’s Analytical Perspective
Late Stage Products (Preregistration)
Comparative Analysis
Umbralisib: TG Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Tenalisib: Rhizen Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I and I/II)
Comparative Analysis
ZX 101A: Nanjing Zenshine Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
AT-104: Applied Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
“Phosphatidylinositol 3 kinase delta inhibitors Key Companies
“Phosphatidylinositol 3 kinase delta inhibitors Key Products
“Phosphatidylinositol 3 kinase delta inhibitors- Unmet Needs
“Phosphatidylinositol 3 kinase delta inhibitors- Market Drivers and Barriers
“Phosphatidylinositol 3 kinase delta inhibitors- Future Perspectives and Conclusion
“Phosphatidylinositol 3 kinase delta inhibitors Analyst Views
“Phosphatidylinositol 3 kinase delta inhibitors Key Companies
Appendix